Bibliography
- GRISWOLD DE, HILLEGASS LM, BRETON JJ, ESSER KM,ADAMS JL: Differentiation in vivo of classical non-steroidal antiinflammatory drugs from cytokine sup-pressive antiinflammatory drugs and other pharma-cological classes using mouse tumour necrosis factor alpha production. Drugs Exp. Clin. Res. (1993) 19:243–248.
- HANSON GJ: Inhibitors of p38 kinase. Exp. Opin. Ther.Patents (1997) 7:729–734.
- •Good review of the early patent literature highlighting the dominant role of SmithKline Beecham.
- HENRY JR, RUPERT K C, DODD JH et al: 6-Amino-2-(4- fluoropheny1)-4-methoxy-3-(4-pyridy1)-1H-py-rrolo[2,3-b]pyridine (RWJ 68354): a potent and selec-tive p38 kinase inhibitor. J. Med. Chem. (1998) 41:4196–4198.
- •First description of a novel p38 kinase inhibitor.
- FRANTZ B, KLATT T, PANG M et al.: The activation stateof p38 mitogen-activated protein kinase determines the efficiency of ATP competition for pyridinylimida-zole inhibitor binding. Biochemistry (1998) 37:13846–13853.
- BADGER AM, BRADBEER JN, VOTTA B, LEE JC, ADAMS JL,GRISWOLD DE: Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune func-tion. J. Pharmacol. Exp. Ther. (1996) 279:1453–1461.
- •The biological activity of the best characterised p38 inhibitor.
- WANG Z, CANAGARAJAH BJ, BOEHM JC et al.: Structural basis of inhibitor selectivity in MAP kinases. Structure (1998) 6:1117–1128.
- ••Crystallographic evidence for the mode of interaction ofthese inhibitors with the p38 kinase.
- ADAMS JL, BOEHM JC, KASSIS S et al.: Pyrimidinylimida- zole inhibitors of CSBP/p38 kinase demonstrating de-creased inhibition of hepatic cytochrome P450 enzymes. Bioorg. Med. Chem. Lett. (1998) 8:3111–3116.
- •Highlights the overlapping SAR requirements that lead to in-hibition of P450 as well as p38 kinase.
- GALLAGHER TF, BOEHM JC, OSIFO IK et al.: Aminopy- rimidinylimidazoles as inhibitors of p38 kinase (CSBP). ACS. Dallas, USA (1998). MEDI 116.